BRPI0417250A - peptìdios e polinucleotìdio isolados e purificados, anticorpos, vetor, célula hospedeira, métodos de inibição de agregação plaquetária, da ligação do fibrinogênio a plaquetas, de uso de polinucleotìdio para a produção de proteìna e de tratamento de pessoa e composições farmacêuticas - Google Patents

peptìdios e polinucleotìdio isolados e purificados, anticorpos, vetor, célula hospedeira, métodos de inibição de agregação plaquetária, da ligação do fibrinogênio a plaquetas, de uso de polinucleotìdio para a produção de proteìna e de tratamento de pessoa e composições farmacêuticas

Info

Publication number
BRPI0417250A
BRPI0417250A BRPI0417250-7A BRPI0417250A BRPI0417250A BR PI0417250 A BRPI0417250 A BR PI0417250A BR PI0417250 A BRPI0417250 A BR PI0417250A BR PI0417250 A BRPI0417250 A BR PI0417250A
Authority
BR
Brazil
Prior art keywords
polynucleotide
antibodies
methods
vector
isolated
Prior art date
Application number
BRPI0417250-7A
Other languages
English (en)
Inventor
Carlos F Barbas
Jenho Chung
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BRPI0417250A publication Critical patent/BRPI0417250A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PEPTìDIOS E POLINUCLEOTìDEO ISOLADOS E PURIFICADOS, ANTICORPOS, VETOR, CéLULA HOSPEDEIRA, MéTODOS DE INIBIçãO DA AGREGAçãO PLAQUETáRIA, DA LIGAçãO DO FIBRINOGêNIO A PLAQUETAS, DE USO DE POLINUCLEOTìDIO PARA A PRODUçãO DE PROTEìNA E DE TRATAMENTO DE PESSOA E COMPOSIçõES FARMACêUTICAS". A presente invenção proporciona anticorpos e petídios específicos da integrina <244>~ IIB~<225>~ 3~. Os anticorpos e peptídios demonstram pouca ou nenhuma imunorreatividade com outras integrinas. São também providos métodos de inibição da agregação plaquetária que usam os anticorpos e peptídios.
BRPI0417250-7A 2003-12-03 2004-12-03 peptìdios e polinucleotìdio isolados e purificados, anticorpos, vetor, célula hospedeira, métodos de inibição de agregação plaquetária, da ligação do fibrinogênio a plaquetas, de uso de polinucleotìdio para a produção de proteìna e de tratamento de pessoa e composições farmacêuticas BRPI0417250A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52685903P 2003-12-03 2003-12-03
PCT/US2004/040381 WO2005056575A2 (en) 2003-12-03 2004-12-03 INTEGRIN αIIbβ3 SPECIFIC ANTIBODIES AND PEPTIDES

Publications (1)

Publication Number Publication Date
BRPI0417250A true BRPI0417250A (pt) 2007-03-06

Family

ID=34676670

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417250-7A BRPI0417250A (pt) 2003-12-03 2004-12-03 peptìdios e polinucleotìdio isolados e purificados, anticorpos, vetor, célula hospedeira, métodos de inibição de agregação plaquetária, da ligação do fibrinogênio a plaquetas, de uso de polinucleotìdio para a produção de proteìna e de tratamento de pessoa e composições farmacêuticas

Country Status (12)

Country Link
US (1) US8586033B2 (pt)
EP (1) EP1694349B1 (pt)
JP (1) JP2008501305A (pt)
KR (1) KR20070009978A (pt)
CN (2) CN102653559B (pt)
AU (1) AU2004297202B2 (pt)
BR (1) BRPI0417250A (pt)
CA (1) CA2548243A1 (pt)
ES (1) ES2436170T3 (pt)
MX (1) MXPA06006319A (pt)
WO (1) WO2005056575A2 (pt)
ZA (1) ZA200605419B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577292T3 (es) * 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
WO2007139359A1 (en) * 2006-05-31 2007-12-06 Hanwha Chemical Corporation Vcam-1 specific monoclonal antibody
WO2008017859A2 (en) * 2006-08-10 2008-02-14 Isis Innovation Limited Ligand for the g6b receptor on blood platelets
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
EP2826790B1 (en) 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE4336758A1 (de) * 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
PL345574A1 (en) * 1998-07-06 2001-12-17 Scripps Research Inst Angiogenesis inhibitors
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
ES2288900T3 (es) * 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.

Also Published As

Publication number Publication date
CN102653559A (zh) 2012-09-05
MXPA06006319A (es) 2006-08-23
AU2004297202A1 (en) 2005-06-23
EP1694349A4 (en) 2010-07-07
ZA200605419B (en) 2007-04-25
CN102653559B (zh) 2014-09-10
JP2008501305A (ja) 2008-01-24
EP1694349A2 (en) 2006-08-30
CN1901930A (zh) 2007-01-24
ES2436170T3 (es) 2013-12-27
EP1694349B1 (en) 2013-10-09
US20100297101A1 (en) 2010-11-25
AU2004297202B2 (en) 2011-08-25
CN1901930B (zh) 2012-05-30
WO2005056575A3 (en) 2006-02-16
KR20070009978A (ko) 2007-01-19
US8586033B2 (en) 2013-11-19
WO2005056575A2 (en) 2005-06-23
CA2548243A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
BRPI0414722A (pt) meios sem produto animal e processos para obtenção de uma toxina botulìnica
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
EP2368907A3 (en) Anti-Abeta antibodies and their use
TNSN07069A1 (en) Process for concentration of antibodies and therapeutic products thereof
BRPI0507489A (pt) anticorpos humanos de anti-cd38 e para os seus usos
BR0208338A (pt) Derivados de piridina
UA87549C2 (en) PREPARATION WHICH CONTAINS the HUMANIZED MONOKLONAL&#39;NOE ANTIBODY 3D6, THAT SPECIFICALLY ZV&#39;&#39;YAZUET&#39;SYA From BETA-AMILOIDNIM by PEPTID, And PHARMACEUTICAL PRODUCT
EA200500644A1 (ru) Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
EP3002294B8 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
UA91815C2 (ru) Выделенное антитело, которое специфически связывает gdf-8, и его применение
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BR0306973A (pt) Anticorpos anti-igf-ir e respectivas aplicações
BRPI0507026A (pt) proteìnas de fusão de albumina
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2005097185A3 (en) Irta-5 antibodies and their uses
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
Tamamura et al. Downsizing of an HIV–cell fusion inhibitor, T22 ([Tyr5, 12, Lys7]-Polyphemusin II), with the maintenance of anti-HIV activity and solution structure1
WO2005035495A3 (en) Fibrinogen receptor antagonists and their use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2243 DE 31/12/2013.